ObjectiveTo investigate BCL 6 gene mutations in Chinese populations with B cell non Hodgkin's lymphoma Methods Polymerase chain reaction (PCR), denaturing gradient gel electrophoresis (DGGE) and direct D...ObjectiveTo investigate BCL 6 gene mutations in Chinese populations with B cell non Hodgkin's lymphoma Methods Polymerase chain reaction (PCR), denaturing gradient gel electrophoresis (DGGE) and direct DNA sequencing were used to identify mutations in the 5' noncoding region of the BCL 6 gene in a total of 40 cases of diffuse large cell lymphoma (DLCL) and follicular lymphoma (FL) Results Nine cases were found to have base substitutions The incidence of BCL 6 gene mutation and the frequency of single base changes were approximately 25 7% and (0 56-1 10)×10 2 /bp, respectively Conclusions The 5' regulatory region of the BCL 6 gene undergoes frequent somatic hypermutation during lymphomagenesis and the identification of BCL 6 gene hypermutations provides a molecular marker for confirmatory diagnosis of B NHL展开更多
Objective The aim of this study was to explore the mechanism behind lncRNA small nucleolar RNA host gene 19(lncRNA SNHG19)/microrNA-299-5P(miR-299-5p)/mitogen-activated protein kinase 6(MAPK6)signaling axis promoting ...Objective The aim of this study was to explore the mechanism behind lncRNA small nucleolar RNA host gene 19(lncRNA SNHG19)/microrNA-299-5P(miR-299-5p)/mitogen-activated protein kinase 6(MAPK6)signaling axis promoting metastasis of non-small cell lung cancer(NSCLC).Methods To analyze the abnormal expression of lncRNAs in NSCLC,50 surgically resected NSCLC and adjacent tissue samples were collected from August 2021 to August 2022.The mRNA expression levels of lncRNA SNHG19,Mir-299-5p,and MAPK6 were detected by qRT-PCR.The functions of lncRNA SNHG19,Mir-299-5p and MAPK6 were investigated by CCK-8,clone formation,EdU,scratch,Transwell western blotting(WB)and in vivo xenograft assay.RNA fluorescence in-situ hybridization(FISH),RNA pull-down,dual luciferase reporter,and RNA co-immunoprecipitation assays were used to explore the mechanism of action between lncRNA SNHG19,miR-299-5p,and MAPK6.Results High expression of lncRNA SNHG19 was correlated with poor prognosis,tumor size,lymph node metastasis,and TNM stage in NSCLC patients(P<0.05).Cell function experiments showed that lncRNA SNHG19 could improve the proliferation,clone formation,migration,and invasion ability of A549 cells both in vitro and in vivo(all P<0.05)and increased the relative expression levels of vimentin and MAPK6(P<0.05).The relative expression level of E-cadherin was decreased(P<0.05).lncRNA SNHG19 can interact with Mir-299-5p and regulate the expression level of MAPK6.Conclusion lncRNA SNHG19 is upregulated in NSCLC tissues and cells,and its high expression is associated with tumor progression and poor survival.Moreover,it can act as a molecular sponge for Mir-299-5p to regulate MAPK6 expression and promote the proliferation and metastasis of A549 cells.展开更多
Prostate cancer is one of the most prevalent malignant tumors in men worldwide,and early diagnosis is essential to improve patient survival.This review provides a comprehensive discussion of recent advances in prostat...Prostate cancer is one of the most prevalent malignant tumors in men worldwide,and early diagnosis is essential to improve patient survival.This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers,including molecular,cellular,and exosomal biomarkers.The potential of various biomarkers such as gene fusions(TMPRSS2-ERG),noncoding RNAs(SNHG12),proteins(PSA,PSMA,AR),and circulating tumor cells(CTCs)in the diagnosis,prognosis,and targeted therapies of prostate cancer is emphasized.In addition,this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications.In addition,this review provides insights into the development of specific probes,including fluorescent,electrochemical,and radionuclide probes,for sensitive and accurate detection of prostate cancer biomarkers.In conclusion,this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research,emphasizing the potential for precision diagnosis and targeted therapy.展开更多
基金ThisworkwassupportedbythegrantsfromtheNationalNaturalScienceFoundationofChina (No 3 9770 83 0 ) andDr ClydeFoundation
文摘ObjectiveTo investigate BCL 6 gene mutations in Chinese populations with B cell non Hodgkin's lymphoma Methods Polymerase chain reaction (PCR), denaturing gradient gel electrophoresis (DGGE) and direct DNA sequencing were used to identify mutations in the 5' noncoding region of the BCL 6 gene in a total of 40 cases of diffuse large cell lymphoma (DLCL) and follicular lymphoma (FL) Results Nine cases were found to have base substitutions The incidence of BCL 6 gene mutation and the frequency of single base changes were approximately 25 7% and (0 56-1 10)×10 2 /bp, respectively Conclusions The 5' regulatory region of the BCL 6 gene undergoes frequent somatic hypermutation during lymphomagenesis and the identification of BCL 6 gene hypermutations provides a molecular marker for confirmatory diagnosis of B NHL
文摘Objective The aim of this study was to explore the mechanism behind lncRNA small nucleolar RNA host gene 19(lncRNA SNHG19)/microrNA-299-5P(miR-299-5p)/mitogen-activated protein kinase 6(MAPK6)signaling axis promoting metastasis of non-small cell lung cancer(NSCLC).Methods To analyze the abnormal expression of lncRNAs in NSCLC,50 surgically resected NSCLC and adjacent tissue samples were collected from August 2021 to August 2022.The mRNA expression levels of lncRNA SNHG19,Mir-299-5p,and MAPK6 were detected by qRT-PCR.The functions of lncRNA SNHG19,Mir-299-5p and MAPK6 were investigated by CCK-8,clone formation,EdU,scratch,Transwell western blotting(WB)and in vivo xenograft assay.RNA fluorescence in-situ hybridization(FISH),RNA pull-down,dual luciferase reporter,and RNA co-immunoprecipitation assays were used to explore the mechanism of action between lncRNA SNHG19,miR-299-5p,and MAPK6.Results High expression of lncRNA SNHG19 was correlated with poor prognosis,tumor size,lymph node metastasis,and TNM stage in NSCLC patients(P<0.05).Cell function experiments showed that lncRNA SNHG19 could improve the proliferation,clone formation,migration,and invasion ability of A549 cells both in vitro and in vivo(all P<0.05)and increased the relative expression levels of vimentin and MAPK6(P<0.05).The relative expression level of E-cadherin was decreased(P<0.05).lncRNA SNHG19 can interact with Mir-299-5p and regulate the expression level of MAPK6.Conclusion lncRNA SNHG19 is upregulated in NSCLC tissues and cells,and its high expression is associated with tumor progression and poor survival.Moreover,it can act as a molecular sponge for Mir-299-5p to regulate MAPK6 expression and promote the proliferation and metastasis of A549 cells.
基金funded by the National Natural Science Foundation of China(32101153)Young Elite Scientists Sponsorship Program by BATSA(BYESS2023244)the Beijing Institute of Technology Research Fund Program for Young Scholars.
文摘Prostate cancer is one of the most prevalent malignant tumors in men worldwide,and early diagnosis is essential to improve patient survival.This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers,including molecular,cellular,and exosomal biomarkers.The potential of various biomarkers such as gene fusions(TMPRSS2-ERG),noncoding RNAs(SNHG12),proteins(PSA,PSMA,AR),and circulating tumor cells(CTCs)in the diagnosis,prognosis,and targeted therapies of prostate cancer is emphasized.In addition,this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications.In addition,this review provides insights into the development of specific probes,including fluorescent,electrochemical,and radionuclide probes,for sensitive and accurate detection of prostate cancer biomarkers.In conclusion,this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research,emphasizing the potential for precision diagnosis and targeted therapy.
